Evidence map›Paper›PMID 40034691›Full record

ArticleFrontiers in immunology2025

Hypomethylation of

De-Hong Wu, Hong-Chun Qiu, Jing Xu, Jiang Lin, Jun Qian

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

De-Hong WuDeparrtment of Central Lab, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Hong-Chun QiuDeparrtment of Hematology, KunShan Third People's Hospital, Kunshan, Jiangsu, China.
Jing XuDeparrtment of Hematology, KunShan Third People's Hospital, Kunshan, Jiangsu, China.
Jiang LinDeparrtment of Central Lab, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Jun QianDeparrtment of Central Lab, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The function of Methods: Multiple datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas projects (TCGA) were used to explore the expression and methylation profile of GCNT2 in normal hematopoiesis and AML. A pan-cancer analysis was performed to define the survival implications of GCNT2 across multiple cancers including AML. The relationships between GCNT2 expression/methylation and clinicopathologic features were investigated using a TCGA-AML dataset. Correlation analysis was performed to explore the relationship between transcriptional expression and DNA methylation. Differentially expressed genes (DEGs) on the KEGG pathway and GO terms were visualized using DAVID. Gene Set Enrichment Analysis (GESA) was carried out to assess the underlying mechanism. The relationship between methylation and immune cell infiltration was also examined. Results: Conclusions: Our comprehensive research demonstrated that

Indexed as

DNA MethylationGene Expression Regulation, LeukemicLeukemia, Myeloid, AcuteBiomarkers, TumorEpigenesis, GeneticFemaleGene Expression ProfilingHumansMaleMiddle AgedPrognosisProtein IsoformsBiomarkers, TumorProtein Isoformsacute myeloid leukemiaDNA methylationGCNT2immunotherapystemness scoressurvival

Identifiers

PMID40034691
PMCPMC11873079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.